Table 1.

Nonmetallic and organometallics CO-releasing molecules (CORM’s) fragments exhibited therapeutics activities.

List	CORMs	Therapeutic Implications	Refs
1	CORM-1	Increase coronary perfusion pressures; attenuates the L-NAME-mediated; restore unstable blood pressure and modulates vessel contractility ex-vivo in animals.	[95]
2	CORM-2	Attenuates inflammatory response in lungs and liver; induces vasorelaxation; protects against IRI; activates K+/Ca+2 channels; possible for pulmonary hypertension.	[95,96]
3	CORM-3	Improves the liver & kidney functions during transplantation; Vasorelaxation induction; prevents sepsis & cardiac graft rejection; helps in bacterial infections; support rheumatoid arthritis; RBF improvement in the treatment of cynomolgus for monkeys.	[23,28,71,97,98,99]
4	CORM-401	Improves insulin-sensitivity and metabolic switch induces in adipocytes.	[100]
5	ALF492	In severe malaria, fully protects with artesunate combination.	[101]
6	CORM-A1	Induces the vasorelaxation; Increases RBF and reduced vascular; gives resistance in the kidney of mice; good cerebroprotective agent for epileptic seizures treatments.	[102]
7	Re-CORM-1	Anti-oxidative characteristic and protects against IRI from the affected neonatal rat of cardiomyocytes.	[103]
8	B12-ReCORM-2	Protects against IRI (neonatal rat cardio-myocyte); hindrance cell mortality up to 80%; support the cardiac repairing and cardiac disease (ameliorates degenerative); anti-oxidative agent; augments and direct cardiomyogenesis.	[104,105]
9	3-hydroxyflavon CORMs	Exerting anti-oxidative activity; anti-inflammatory services and anti-cancer effects.	[46,55,89]
10	ALF 186	Protective effects for gastric ulcers and neuro protective, while IRI-induced apoptosis of retinal ganglion cells (RGC).	[106,107,108,109]
11	CORMA-1-PLA	Prevents fibroblasts and internalized into 3T3 cells during metabolic and hypoxia depletion conditions.	[110]
12	α-DK-CORMs	Absorbs in acute myeloid leukemia (AML) KG-1 cells and releases CO In-vivo upon 470nm irradiation.	[111]